Human enteroviruses

Infectious Diseases: Third Edition

Volumn 2, Issue , 2010, Pages 1528-1538

  Palacios, Gustavo ^a   Casas, Inmaculada ^b   Trallero, Gloria ^b  

^a Mailman School of Public Health Columbia University ^*  (United States)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906813046     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04579-7.00153-2     Document Type: Chapter

References (72)

1. Stanway G., Brown F., Christian P., et al. Family Picornaviridae. Virus taxonomy 2005, 757-778. Academic Press, London, Eighth Report of the International Committee on Taxonomy of Viruses. C.M. Fauquet, M.A. Mayo, J. Maniloff, U. Desselberger, L.A. Ball (Eds.).
2. Oberste M., Schnurr D., Maher K., al-Busaidy S., Pallansch M. Molecular identification of new picornaviruses and characterization of a proposed enterovirus 73 serotype. J Gen Virol 2001, 82:409-416.
3. Oberste M.S., Maher K., Flemister M.R., Marchetti G., Kilpatrick D.R., Pallansch M.A. Comparison of classic and molecular approaches for the identification of untypeable enteroviruses. J Clin Microbiol 2000, 38:1170-1174.
4. Oberste M.S., Maher K., Michele S.M., Belliot G., Uddin M., Pallansch M.A. Enteroviruses 76, 89, 90 and 91 represent a novel group within the species human enterovirus A. J Gen Virol 2005, 86:445-451.
5. Oberste M.S., Maher K., Nix W.A., et al. Molecular identification of 13 new enterovirus types, EV79-88, EV97, and EV100-101, members of the species human enterovirus B. Virus Res 2007, 128:34-42.
6. Oberste M.S., Michele S.M., Maher K., et al. Molecular identification and characterization of two proposed new enterovirus serotypes, EV74 and EV75. J Gen Virol 2004, 85:3205-3212.
7. Smura T.P., Junttila N., Blomqvist S., et al. Enterovirus 94, a proposed new serotype in human enterovirus species D. J Gen Virol 2007, 88:849-858.
8. Junttila N., Leveque N., Kabue J.P., et al. New enteroviruses, EV-93 and EV-94, associated with acute flaccid paralysis in the Democratic Republic of the Congo. J Med Virol 2007, 79:393-400.
9. Hogle J.M., Chow M., Filman D.J. Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 1985, 229:1358-1365.
10. McCaren L.C., Holland J.J., Syverton J.T. The mammalian cell-virus relationship. I. Attachment of poliovirus to cultivated cells of primate and non-primate origin. J Exp Med 1959, 109:475-485.
11. Koike S., Taya C., Kurata T., et al. Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci USA 1991, 88:951-955.
12. Racaniello V.R. One hundred years of poliovirus pathogenesis. Virology 2006, 344:9-16.
13. Zhang G., Haydon D.T., Knowles N.J., McCauley J.W. Molecular evolution of swine vesicular disease virus. J Gen Virol 1999, 80(Pt.3):639-651.
14. Ida-Hosonuma M., Iwasaki T., Yoshikawa T., et al. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol 2005, 79:4460-4469.
15. Flodstrom-Tullberg M., Hultcrantz M., Stotland A., et al. RNase L and double-stranded RNA-dependent protein kinase exert complementary roles in islet cell defense during coxsackievirus infection. J Immunol 2005, 174:1171-1177.
16. Scheuner D., Gromeier M., Davies M.V., et al. The double-stranded RNA-activated protein kinase mediates viral-induced encephalitis. Virology 2003, 317:263-274.
17. Plotkin S.A., Vidor E. Poliovirus vaccine - inactivated. Vaccines 2004, Vol. 1:625-649. WB Saunders, Philadelphia. S.A. Plotkin, W.A. Orenstein (Eds.).
18. Sutter R.W., Kew O.M., Cochi S.L. Poliovirus vaccine - live. Vaccines 2004, Vol 1:651-705. Philadelphia, WB Saunders. S.A. Plotkin, W.A. Orenstein (Eds.).
19. Melnick J.L. Advantages and disadvantages of killed and live poliomyelitis vaccines. Bull World Health Organ 1978, 56:21-38.
20. Robbins F.C. The history of polio vaccine development. Vaccines 2004, Vol 1:17-30. WB Saunders, Philadelphia. S.A. Plotkin, W.A. Orenstein (Eds.).
21. Anon Transmission of wild poliovirus type 2 - apparent global interruption. Wkly Epidemiol Rec 2001, 76:95-97.
22. Anon Poliomyelitis outbreak escalates in the Sudan. Wkly Epidemiol Rec 2005, 80:2-3.
23. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005, 59:587-635.
24. Agol V.I., Chumakov K., Ehrenfeld E., Wimmer E. Don't drop current vaccine until we have new ones. Nature 2005, 435:881.
25. Dowdle W.R., De Gourville E., Kew O.M., Pallansch M.A., Wood D.J. Polio eradication: the OPV paradox. Rev Med Virol 2003, 13:277-291.
26. Racaniello V.R. It is too early to stop polio vaccination. Bull World Health Organ 2000, 78:359-360.
27. Mueller S., Papamichail D., Coleman J.R., Skiena S., Wimmer E. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J Virol 2006, 80:9687-9696.
28. Macadam A.J., Ferguson G., Stone D.M., et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol 2006, 80:8653-8663.
29. Vignuzzi M., Wendt E., Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med 2008, 14:154-161.
30. Langford M.P., Kadi R.M., Ganley J.P., Yin-Murphy M. Inhibition of epidemic isolates of coxsackievirus type A 24 by recombinant and natural interferon alpha and interferon beta. Intervirology 1988, 29:320-327.
31. Abzug M.J., Keyserling H.L., Lee M.L., Levin M.J., Rotbart H.A. Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis 1995, 20:1201-1206.
32. Pevear D.C., Tull T.M., Seipel M.E., Groarke J.M. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 1999, 43:2109-2115.
33. Eggers H.J. Assays systems: testing of antiviral drugs in cell cultures (in vitro). Antiviral drug development 1988, Vol 1:139-148. Plenum Press, New York. E. de Clercq, R.T. Walker (Eds.).
34. Melnick J.L., Wimberly I.L. Lyophilized combination pools of enterovirus equine antisera: new LBM pools prepared from reserves of antisera stored frozen for two decades. Bull World Health Organ 1985, 63:543-550.
35. Melnick J.L., Schmidt N.J., Hampil B., Ho H.H. Lyophilized combination pools of enterovirus equine antisera: preparation and test procedures for the identification of field strains of 19 group A coxsackievirus serotypes. Intervirology 1977, 8:172-181.
36. Bell E.J., McCartney R.A. A study of Coxsackie B virus infections, 1972-1983. J Hyg 1984, 93:197-203.
37. Danes L., Jaresova I. Neutralization microtest with human coxsackievirus and echovirus serotypes. J Hyg Epidemiol Microbiol Immunol 1985, 29:399-408.
38. Manjunath N., Balaya S., Seth P. Serologic survey for neutralizing antibodies against group B coxsackieviruses in normal population in Delhi area. Ind J Med Res 1982, 76:656-661.
39. Mukundan P., John T.J. Prevalence and titres of neutralising antibodies to group B coxsackieviruses. Ind J Med Res 1983, 77:577-589.
40. Santhanam S., Choudhury D.S. Antibodies against coxsackie B2 virus in infants and children in Delhi. J Commun Dis 1984, 16:304-306.
41. Morag A., Margalith M., Shuval H.I., Fattal B. Acquisition of antibodies to various Coxsackie and Echo viruses and hepatitis A virus in agricultural communal settlements in Israel. J Med Virol 1984, 14:39-47.
42. Margalith M., Fattal B., Shuval H.I., Morag A. Prevalence of antibodies to enteroviruses and varicella-zoster virus among residents and overseas volunteers at agricultural settlements in Israel. J Med Virol 1986, 20:189-197.
43. Lau R.C. Coxsackie B virus infections in New Zealand patients with cardiac and non-cardiac diseases. J Med Virol 1983, 11:131-137.
44. Oberste M.S., Maher K., Williams A.J., et al. Species-specific RT-PCR amplification of human enteroviruses: a tool for rapid species identification of uncharacterized enteroviruses. J Gen Virol 2006, 87:119-128.
45. Kessler H.H., Santner B., Rabenau H., et al. Rapid diagnosis of enterovirus infection by a new one-step reverse transcription-PCR assay. J Clin Microbiol 1997, 35:976-977.
46. Oberste M.S., Maher K., Kilpatrick D.R., Pallansch M.A. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J Virol 1999, 73:1941-1948.
47. Palacios G., Casas I., Tenorio A., Freire C. Molecular identification of enterovirus by analyzing a partial VP1 genomic region with different methods. J Clin Microbiol 2002, 40:182-192.
48. Casas I., Palacios G.F., Trallero G., Cisterna D., Freire M.C., Tenorio A. Molecular characterization of human enteroviruses in clinical samples: comparison between VP2, VP1, and RNA polymerase regions using RT nested PCR assays and direct sequencing of products. J Med Virol 2001, 65:138-148.
49. Caro V., Guillot S., Delpeyroux F., Crainic R. Molecular strategy for 'serotyping' of human enteroviruses. J Gen Virol 2001, 82:79-91.
50. Manzara S., Muscillo M., La Rosa G., Marianelli C., Cattani P., Fadda G. Molecular identification and typing of enteroviruses isolated from clinical specimens. J Clin Microbiol 2002, 40:4554-4560.
51. Oberste M.S., Maher K., Kilpatrick D.R., Flemister M.R., Brown B.A., Pallansch M.A. Typing of human enteroviruses by partial sequencing of VP1. J Clin Microbiol 1999, 37:1288-1293.
52. Norder H., Bjerregaard L., Magnius L.O. Homotypic echoviruses share aminoterminal VP1 sequence homology applicable for typing. J Med Virol 2001, 63:35-44.
53. Oberste M.S., Maher K., Flemister M.R., Marchetti G., Kilpatrick D.R., Pallansch M.A. Comparison of classic and molecular approaches for the identification of untypeable enteroviruses. J Clin Microbiol 2000, 38:1170-1174.
54. Oberste M.S., Nix W.A., Maher K., Pallansch M.A. Improved molecular identification of enteroviruses by RT-PCR and amplicon sequencing. J Clin Virol 2003, 26:375-377.
55. Ishiko H., Shimada Y., Yonaha M., et al. Molecular diagnosis of human enteroviruses by phylogeny-based classification by use of the VP4 sequence. J Infect Dis 2002, 185:744-754.
56. Arola A., Santti J., Ruuskanen O., Halonen P., Hyypia T. Identification of enteroviruses in clinical specimens by competitive PCR followed by genetic typing using sequence analysis. J Clin Microbiol 1996, 34:313-318.
57. Santti J., Vainionpää R., Hyypiä T. Molecular detection and typing of human picornaviruses. Virus Res 1999, 62:177-183.
58. Casas I., Palacios G.F., Trallero G., Cisterna D., Freire M.C., Tenorio A. Molecular characterization of human enteroviruses in clinical samples: comparison between VP2, VP1, and RNA polymerase regions using RT nested PCR assays and direct sequencing of products. J Med Virol 2001, 65:138-148.
59. Oberste M.S., Penaranda S., Maher K., Pallansch M.A. Complete genome sequences of all members of the species human enterovirus A. J Gen Virol 2004, 85:1597-1607.
60. Brown B., Oberste M.S., Maher K., Pallansch M.A. Complete genomic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the noncapsid coding region. J Virol 2003, 77:8973-8984.
61. Lindberg A.M., Andersson P., Savolainen C., Mulders M.N., Hovi T. Evolution of the genome of human enterovirus B: incongruence between phylogenies of the VP1 and 3CD regions indicates frequent recombination within the species. J Gen Virol 2003, 84:1223-1235.
62. Lukashev A.N., Lashkevich V.A., Ivanova O.E., Koroleva G.A., Hinkkanen A.E., Ilonen J. Recombination in circulating enteroviruses. J Virol 2003, 77:10423-10431.
63. Lukashev A.N., Lashkevich V.A., Koroleva G.A., Ilonen J., Hinkkanen A.E. Recombination in uveitis-causing enterovirus strains. J Gen Virol 2004, 85:463-470.
64. Norder H., Bjerregaard L., Magnius L.O. Open reading frame sequence of an Asian enterovirus 73 strain reveals that the prototype from California is recombinant. J Gen Virol 2002, 83:1721-1728.
65. Norder H., Bjerregaard L., Magnius L., Lina B., Aymard M., Chomel J.-J. Sequencing of 'untypable' enteroviruses reveals two new types, EV-77 and EV-78, within human enterovirus type B and substitutions in the BC loop of the VP1 protein for known types. J Gen Virol 2003, 84:827-836.
66. Palacios G., Casas I., Cisterna D., Trallero G., Tenorio A., Freire C. Molecular epidemiology of echovirus 30: temporal circulation and prevalence of single lineages. J Virol 2002, 76:4940-4949.
67. Pallansch M.A., Oberste M.S. Coxsackievirus, echovirus, and other enteroviruses. Infectious diseases 2004, Lippincott, Williams and Wilkins, Philadelphia. 3rd ed. S.L. Gorbach, J.G. Bartlett, N.R. Blacklow (Eds.).
68. Oberste M.S., Maher K., Kennett M.L., et al. Molecular epidemiology and genetic diversity of echovirus type 30 (E30): genotypes correlate with temporal dynamics of E30 isolation. J Clin Microbiol 1999, 37:3928-3933.
69. Savolainen C., Hovi T., Mulders M.N. Molecular epidemiology of echovirus 30 in Europe: succession of dominant sublineages within a single major genotype. Arch Virol 2001, 146:521-537.
70. Mulders M.N., Salminen M., Kalkkinen N., Hovi T. Molecular epidemiology of coxsackievirus B4 and disclosure of the correct VP1/2A(pro) cleavage site: evidence for high genomic diversity and long-term endemicity of distinct genotypes. J Gen Virol 2000, 81:803-812.
71. Witso E., Palacios G., Cinek O., et al. High prevalence of human enterovirus A infections in natural circulation of human enteroviruses. J Clin Microbiol 2006, 44:4095-4100.
72. Nix W.A., Oberste M.S., Pallansch M.A. Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens. J Clin Microbiol 2006, 44:2698-2704.